Molina Healthcare (MOH) Valuation Reassessed After Medicare 2027 Payment Rate Decision

Medicare payment update sparks fresh look at Molina Healthcare stock

The recent Centers for Medicare & Medicaid Services decision on 2027 Medicare payment rates has put Molina Healthcare (MOH) back in focus, as investors reassess a business closely tied to government funded health programs.

See our latest analysis for Molina Healthcare.

Recent trading shows how sensitive Molina Healthcare’s share price is to policy news, with the 6% move around the Medicare payment update followed by a 3.21% gain on April 6. However, the 90 day share price return of 19.77% and 1 year total shareholder return of 57.72% both point to momentum that has been fading over time.

If policy headlines have you looking beyond a single insurer, this is a good moment to scan for other healthcare names linked to AI using our focused stock screener, starting with 31 healthcare AI stocks.

With the stock down over the past year and trading only about 4% below the average analyst target, the central question is whether Molina is quietly undervalued or whether the market already recognizes the growth that lies ahead.

Most Popular Narrative: 64.6% Undervalued

Molina Healthcare’s last close at $145.88 sits well below the narrative fair value of $411.65, setting up a wide valuation gap that hinges on growth and margins in government backed plans.

Catalysts

• Membership Growth: MOH has seen a 9% increase in members year over year, reaching approximately 5.7 million members as of March 31, 2024. This growth is driven by new contract wins, acquisitions, and expansion.

Read the complete narrative.

Want to see how that membership engine feeds into projected revenue, earnings, and profit margins according to WallStreetWontons? The full narrative lays out the assumptions step by step.

Result: Fair Value of $411.65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on policy staying constructive; tighter regulation or higher medical costs could quickly challenge margins and the idea that Molina is materially mispriced.

Find out about the key risks to this Molina Healthcare narrative.

Next Steps

With sentiment split between opportunity and risk, this is a good time to look through the data yourself, weigh both sides, and check the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Molina has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not late to the next move.

• Spot potential value opportunities early by scanning 58 high quality undervalued stocks, which combine solid fundamentals with room for the market to reassess them.
• Strengthen your income game by reviewing 11 dividend fortresses, which aim to pair higher yields with resilient business profiles.
• Prioritize resilience by checking 72 resilient stocks with low risk scores, designed to keep overall portfolio risk in check while still offering room for upside.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com